Company Description
Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in t...
Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.
Valuation
Price to Sales Ratio
253.61
Price to Book Ratio
8.47
Enterprise Value to EBITDA
-10.52
Enterprise Value to Sales
53.40
Efficiency
Total Asset Turnover
0.03
Liquidity
Current Ratio
6.11
Quick Ratio
6.11
Cash Ratio
5.95
Profitability
Gross Margin
79.15
Operating Margin
-810.37
Pretax Margin
-810.49
Net Margin
-810.49
Return on Assets
-27.19
Return on Equity
-34.18
Return on Total Capital
-31.87
Capital Structure
Total Debt to Total Assets
5.72
Officers and Executives
Name | Age | Officer Since | Title |
---|---|---|---|
Dr. John M. Leonard | 63 | 2014 | Director & Chief Medical Officer |
Mr. Glenn Goddard | 48 | 2018 | Executive VP, Chief Financial & Accounting Officer |
Dr. Laura Sepp-Lorenzino | 60 | 2019 | Chief Scientific Officer & Executive VP |
Dr. Eliana Clark | - | - | Senior Vice President-Technical Operations |
Dr. David Lebwohl | - | 2020 | Chief Medical Officer & Executive Vice President |
Insider Actions
01/05/2023 |
Laura Sepp-Lorenzino EVP, Chief Scientific Officer |
689 | Disposition at $39.1 per share. | 26,939 |
01/05/2023 |
Laura Sepp-Lorenzino EVP, Chief Scientific Officer |
1,641 | Disposition at $38.22 per share. | 62,719 |
01/04/2023 |
John M. Leonard President and CEO; Director |
6,673 | Disposition at $37.21 per share. | 248,302 |
01/04/2023 |
David Lebwohl EVP, Chief Medical Officer |
2,574 | Disposition at $37.21 per share. | 95,778 |
01/04/2023 |
James Basta EVP, General Counsel |
1,138 | Disposition at $37.21 per share. | 42,344 |
01/04/2023 |
Laura Sepp-Lorenzino EVP, Chief Scientific Officer |
2,508 | Disposition at $37.21 per share. | 93,322 |
01/04/2023 |
Derek Hicks EVP, Chief Business Officer |
1,812 | Disposition at $37.21 per share. | 67,424 |
01/04/2023 |
Glenn Goddard EVP, Chief Financial Officer |
2,427 | Disposition at $37.21 per share. | 90,308 |
01/04/2023 |
Eliana Clark EVP, Chief Technical Officer |
1,692 | Disposition at $37.21 per share. | 62,959 |
01/03/2023 |
Eliana Clark EVP, Chief Technical Officer |
231 | Disposition at $34.48 per share. | 7,964 |
01/01/2023 |
John M. Leonard President and CEO; Director |
7,848 | Derivative/Non-derivative trans. at $0 per share. | 0 |
01/01/2023 |
David Lebwohl EVP, Chief Medical Officer |
3,187 | Derivative/Non-derivative trans. at $0 per share. | 0 |
01/01/2023 |
Laura Sepp-Lorenzino EVP, Chief Scientific Officer |
3,500 | Derivative/Non-derivative trans. at $0 per share. | 0 |
01/01/2023 |
Glenn Goddard EVP, Chief Financial Officer |
3,062 | Derivative/Non-derivative trans. at $0 per share. | 0 |
07/01/2022 |
Eliana Clark EVP, Chief Technical Officer |
105 | Disposition at $51.74 per share. | 5,432 |
06/14/2022 |
Fred Ehrenkranz Cohen Director |
5,197 | Award at $0 per share. | 0 |
06/14/2022 |
Caroline D. Dorsa Director |
5,197 | Award at $0 per share. | 0 |
06/14/2022 |
Muna Bhanji Director |
2,014 | Award at $0 per share. | 0 |
06/14/2022 |
John Francis Crowley Director |
5,197 | Award at $0 per share. | 0 |
06/14/2022 |
Jean-Francois B. Formela Director |
5,197 | Award at $0 per share. | 0 |
06/14/2022 |
Frank A. G. M. Verwiel Director |
5,197 | Award at $0 per share. | 0 |
06/14/2022 |
Jesse L. Goodman Director |
5,197 | Award at $0 per share. | 0 |
06/14/2022 |
Georgia Keresty Director |
5,197 | Award at $0 per share. | 0 |
04/28/2022 |
Muna Bhanji Director |
7,954 | Award at $0 per share. | 0 |
03/01/2022 |
John M. Leonard President and CEO; Director |
40,990 | Award at $0 per share. | 0 |
03/01/2022 |
David Lebwohl EVP, Chief Medical Officer |
13,816 | Award at $0 per share. | 0 |
03/01/2022 |
Glenn Goddard EVP, Chief Financial Officer |
12,720 | Award at $0 per share. | 0 |
03/01/2022 |
Eliana Clark EVP, Chief Technical Officer |
10,527 | Award at $0 per share. | 0 |
01/03/2022 |
Derek Hicks EVP, Chief Business Officer |
19,118 | Award at $0 per share. | 0 |
01/01/2022 |
John M. Leonard President and CEO; Director |
2,493 | Disposition at $112.26 per share. | 279,864 |
01/01/2022 |
David Lebwohl EVP, Chief Medical Officer |
1,051 | Disposition at $112.24 per share. | 117,964 |
01/01/2022 |
Glenn Goddard EVP, Chief Financial Officer |
1,013 | Disposition at $112.24 per share. | 113,699 |
01/01/2022 |
John M. Leonard President and CEO; Director |
7,848 | Derivative/Non-derivative trans. at $0 per share. | 0 |
01/01/2022 |
David Lebwohl EVP, Chief Medical Officer |
3,187 | Derivative/Non-derivative trans. at $0 per share. | 0 |
01/01/2022 |
Glenn Goddard EVP, Chief Financial Officer |
3,062 | Derivative/Non-derivative trans. at $0 per share. | 0 |
MarketWatch News on NTLA
-
Intellia Therapeutics stock price target cut to $131 from $173 at Stifel Nicolaus
- Tomi Kilgore
-
Intellia Therapeutics started at overweight with $84 stock price target at Morgan Stanley
- Tomi Kilgore
-
What’s Next for the Healthcare Industry, and How to Invest
- Barron's Online
-
11 Cheap Tech Stocks to Consider After the Earnings Deluge
- Barron's Online
-
10 Stocks Driving the Biotech Resurgence
- Barron's Online
-
Gene-Editor Crispr Therapeutics CEO Sees Positive Catalysts Ahead
- Barron's Online
-
Intellia Therapeutics started at market perform with $54 stock price target at BMO Capital
- Tomi Kilgore
-
Intellia Stock Has Tumbled. There Are Issues With Gene-Editing Patents.
- Barron's Online
-
Intellia Therapeutics upgraded to outperform from perform at Oppenheimer
- Tomi Kilgore
-
Pfizer and Beam Partner to Develop Treatments for 3 Genetic Diseases
- Barron's Online
-
Beam Gets FDA Nod for First Gene-Editing Trial
- Barron's Online
-
Prime Is the Newest Gene Editing, and It's Getting Better
- Barron's Online
-
This Fund Is Winning Big by Betting on Stocks That Help Humanity
- Barron's Online
-
Intellia Therapeutics started at buy with $173 stock price target at Stifel Nicolaus
- Tomi Kilgore
- Loading more headlines...
Other News on NTLA
-
IDNA: Healthcare Dashboard For November
- Seeking Alpha
-
ARKK Bears Are Losing Momentum
- Seeking Alpha
-
Intellia Therapeutics (NTLA) Investor Presentation - Slideshow
- Seeking Alpha
-
Editas Medicine: Q3 Update And 2 Clinical Catalysts To Watch
- Seeking Alpha
-
Prime Medicine: CRISPR 3.0 Company
- Seeking Alpha
-
RGA Investment Advisors Q3 2022 Investment Commentary
- Seeking Alpha
-
Tracking Cathie Wood's ARK Invest 13F Portfolio - Q3 2022 Update
- Seeking Alpha
-
GNOM: ETF Review And Healthcare Dashboard For October
- Seeking Alpha
- Loading more headlines...